It's Brain launches MINDPULSE, the first neuro-cognitive test to scientifically characterize the key elements of decision-making
October 12, 2020
News
Assessing perceptual-motor decision-making abilities to better understand the origin of potential dysfunctions in patients aged 13 to 65: this is the ambition of MindPulse, the 1er A neurocognitive test developed by It's Brain, launching commercially this October. Born from the observation of the incredible lag between clinical tools and research advancements, this test is the result of a long-standing collaboration between researchers and clinicians committed to designing tools that meet the public health challenge posed by the rise in mental health disorders. We spoke with Sandra Suarez, founder of It's Brain, and Guillaume Simon, its CEO, about this project, which has been widely praised by the scientific and medical community and is already highly anticipated by clinicians.
Sandra, you're the one who started this project. Can you tell us how it all began?
Sandra Suarez (SVS): Coming from a background in neuroscience research, and also a clinician, I decided at a particular moment in my life, following a long illness, to give a new direction to my professional path and open a neuropsychology practice. I was then astonished to discover how the cognitive assessment tools available to me as a clinician were completely out of step with the advances in neuroscience research that I, as a researcher, had worked on during the first part of my career. Not only did these tools fail to take into account the new models developed in neuroscience, but they also presented limitations such as being tied to a culture or language, or the impossibility of repeating the test without skewing the results. I therefore asked myself what the ideal tool could do, and that's how the idea for what would become the MindPulse began to germinate in my brain.
So, how does one go from such an idea to the commercialization of a product, as you are about to do?
SVS. By working hard and surrounding myself with the right people! My first ally was my husband, Bertrand Eynard, a mathematical physics researcher. We wanted to create something at the intersection of our two disciplines, and I had this idea for MindPulse, which we ultimately developed together. Once I found the approach that would allow me to successfully complete my project, I submitted it to my former colleagues at the Pasteur Institute, who had moved to Paris-Sud University/CNRS, and to Sylvie Granon at Paris-Sud University, who immediately decided to join me. My friends, neurologists and infectious disease specialists, also gave me tremendous support. In 2019, we filed a joint Paris-Sud University/CNRS patent on our very first prototype, "TIREX," which then evolved considerably before becoming the... MindPulse. The next step was to create a company. So I turned to IncubAlliance Paris-Saclay, where I received training and support, and I quickly decided to find someone to assist me with the more "business" side of the project. That's when Guillaume Simon, a graduate engineer from École Polytechnique and an entrepreneur, joined us to create It's Brain and bring MindPulse to market.
In a few words, can you describe this test for us?
SVS. : MindPulse This test is designed for healthcare professionals seeking to scientifically characterize the key cognitive and psychological elements of decision-making, namely attention, inhibition, and reaction to difficulty. Specifically, it is a digital solution that qualifies and quantifies the cognitive processes underlying an individual's ability to react and make choices, in order to better understand the root causes of dysfunction and thus provide more effective support. To develop it, we collaborated with 110 clinicians, allowing us to calibrate the test on nearly 550 individuals aged 13 to 65. We are therefore now able to offer a rapid (15-minute), precise (measuring an individual's reaction in hundredths of a second), inclusive (based solely on an image system), and patient-tracking test.
Who is it addressed to?
SVS: The version we currently market is aimed at an expert audience, namely: cognitive psychologists and neuropsychologists called upon to measure cognition; physicians treating patients with attention, vigilance, and executive function disorders, for example, to investigate white matter damage such as encephalitis, as appears to be the case with COVID-19; and psychomotor therapists and speech therapists. We plan, in a second phase, to develop a diagnostic range for a less specialized clinical audience and, of course, to develop other types of tests.
The final word is yours, Guillaume. What attracted you to this project? How do you envision the future?
Guillaume Simon Beyond its scientifically innovative nature and therefore its strong potential for development in Europe and internationally, it was the profoundly human dimension of the project that immediately convinced me. Having been a family caregiver myself, I found myself completely aligned with this desire to put the best of science at the service of practitioners and, ultimately, patients. Because improving screening and monitoring tools also means improving people's quality of life! This is, in fact, one of the reasons that, when It's Brain was created, led us to join Handitech at the same time as French Tech. MindPulse This is just the beginning. We have a huge number of projects just waiting to be developed… and which will undoubtedly shake up the world of cognitive neuroscience.
To learn more about It’s brain : https://www.mindpulse.net